EV-pIgR-induced cancer aggressiveness was observed to be reversed by Akt and β-catenin inhibitors, confirming that EV-pIgR activates PDK1/Akt/GSK3β/β-catenin signaling [58]. Here, AKT1 is linked to cancer.